JP2012503669A - 肝炎を治療するためのｐｅｇ−インターフェロン、リバビリンおよびｖｘ−９５０を含む治療レジメ - Google Patents

肝炎を治療するためのｐｅｇ−インターフェロン、リバビリンおよびｖｘ−９５０を含む治療レジメ Download PDF

Info

Publication number
JP2012503669A
JP2012503669A JP2011529223A JP2011529223A JP2012503669A JP 2012503669 A JP2012503669 A JP 2012503669A JP 2011529223 A JP2011529223 A JP 2011529223A JP 2011529223 A JP2011529223 A JP 2011529223A JP 2012503669 A JP2012503669 A JP 2012503669A
Authority
JP
Japan
Prior art keywords
weeks
administered
stage
ribavirin
peginterferon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011529223A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012503669A5 (enExample
Inventor
ロバート・エス・コーフマン
シリル・ジャン・カミーユ・ティテュー
レイモン・ポロ
ルドルフ・ペーテル・ヘルハルト・ファン・ヘースウェイク
マリア・グロリア・ビューモント
ガストン・ラファエル・ピッチオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2012503669A publication Critical patent/JP2012503669A/ja
Publication of JP2012503669A5 publication Critical patent/JP2012503669A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2011529223A 2008-09-24 2009-09-24 肝炎を治療するためのｐｅｇ−インターフェロン、リバビリンおよびｖｘ−９５０を含む治療レジメ Pending JP2012503669A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US9984908P 2008-09-24 2008-09-24
US61/099,849 2008-09-24
US10965508P 2008-10-30 2008-10-30
US61/109,655 2008-10-30
US24304109P 2009-09-16 2009-09-16
US61/243,041 2009-09-16
PCT/US2009/058218 WO2010036799A1 (en) 2008-09-24 2009-09-24 Therapeutic regimen comprising peg- interferon, ribavirin and vx-950 for the treatment of hepatitis "

Publications (2)

Publication Number Publication Date
JP2012503669A true JP2012503669A (ja) 2012-02-09
JP2012503669A5 JP2012503669A5 (enExample) 2012-11-08

Family

ID=41396114

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011529223A Pending JP2012503669A (ja) 2008-09-24 2009-09-24 肝炎を治療するためのｐｅｇ−インターフェロン、リバビリンおよびｖｘ−９５０を含む治療レジメ

Country Status (11)

Country Link
US (2) US20110236351A1 (enExample)
EP (1) EP2328656A1 (enExample)
JP (1) JP2012503669A (enExample)
KR (1) KR20110074870A (enExample)
CN (1) CN102316935A (enExample)
AU (1) AU2009296653A1 (enExample)
CA (1) CA2738477A1 (enExample)
EA (1) EA201170484A1 (enExample)
IL (1) IL211810A0 (enExample)
MX (1) MX2011003121A (enExample)
WO (1) WO2010036799A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
EA201170441A1 (ru) * 2008-10-15 2012-05-30 Интермьюн, Инк. Терапевтические противовирусные пептиды
EP2396028A2 (en) * 2009-02-12 2011-12-21 Vertex Pharmceuticals Incorporated Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir
US20110082182A1 (en) * 2009-10-01 2011-04-07 Intermune, Inc. Therapeutic antiviral peptides
PT107894A (pt) 2011-10-21 2014-10-31 Abbvie Inc Métodos para o tratamento de hcv compreendendo pelo menos dois agentes antivirais de actuação directa, ribavirina, mas não interferão.
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
GB2515942A (en) 2011-10-21 2015-01-07 Abbvie Inc Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501802A (ja) * 2004-06-08 2008-01-24 バーテックス　ファーマシューティカルズ　インコーポレイテッド 医薬組成物
JP2008518943A (ja) * 2004-10-29 2008-06-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｖｘ−９５０を含む剤形およびそれらの投与量レジメン
JP2010528013A (ja) * 2007-05-21 2010-08-19 バーテックス ファーマシューティカルズ インコーポレイテッド Ｖｘ−９５０を含む用量形態およびそれらの投与レジメン

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2650616A1 (en) * 2006-04-26 2007-11-08 Vertex Pharmaceuticals Incorporated Hepatitis c virus infection biomarkers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501802A (ja) * 2004-06-08 2008-01-24 バーテックス　ファーマシューティカルズ　インコーポレイテッド 医薬組成物
JP2008518943A (ja) * 2004-10-29 2008-06-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｖｘ−９５０を含む剤形およびそれらの投与量レジメン
JP2010528013A (ja) * 2007-05-21 2010-08-19 バーテックス ファーマシューティカルズ インコーポレイテッド Ｖｘ−９５０を含む用量形態およびそれらの投与レジメン

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN5012001167; ＭＣＨＵＴＣＨＩＳＯＮ: '［７８６］　ＲＥＳＵＬＴＳ　ＯＦ　ＡＮ　ＩＮＴＥＲＩＭ　ＡＮＡＬＹＳＩＳ　ＯＦ　Ａ　ＰＨＡＳＥ　２　ＳＴＵＤＹ　ＯＦ　ＴＥＬＡＰＲＥＶＩＲ　（ＶＸ-９５０）　以下備考' ＪＯＵＲＮＡＬ　ＯＦ　ＨＥＰＡＴＯＬＯＧＹ Ｖ４６, 20070401, Ｐ　Ｓ２９６, ＭＵＮＫＳＧＡＡＲＤ　ＩＮＴＥＲＮＡＴＩＯＮＡＬ　ＰＵＢＬＩＳＨＥＲＳ *
JPN5012001169; ＲＥＥＳＩＮＫ: 'ＲＡＰＩＤ　ＤＥＣＬＩＮＥ　ＯＦ　ＶＩＲＡＬ　ＲＮＡ　ＩＮ　ＨＥＰＡＴＩＴＩＳ　Ｃ　ＰＡＴＩＥＮＴＳ　ＴＲＥＡＴＥＤ　ＷＩＴＨ　ＶＸ-９５０：　以下備考' ＧＡＳＴＲＯＥＮＴＥＲＯＬＯＧＹ Ｖ１３１　Ｎ４, 20061010, Ｐ９９７-１００２, ＥＮＳＥＶＩＥＲ *
JPN5012001170; ＲＥＶＩＬＬ　Ｐ: 'ＴＥＬＡＰＲＥＶＩＲ：　ＨＣＶ　ＮＳ３　ＰＲＯＴＥＡＳＥ　ＩＮＨＩＢＩＴＯＲ　ＴＲＥＡＴＭＥＮＴ　ＯＦ　ＨＥＰＡＴＩＴＩＳ　Ｃ' ＤＲＵＧＳ　ＯＦ　ＴＨＥ　ＦＵＴＵＲＥ Ｖ３２　Ｎ９, 20070101, Ｐ７８８-７９８ *
JPN6013059939; Ｇａｓｔｒｏｅｎｔｅｒｏｌｏｇｙ Ｖｏｌ．１３１, 2006, ｐ．９５０-９５１ *

Also Published As

Publication number Publication date
CA2738477A1 (en) 2010-04-01
MX2011003121A (es) 2011-04-21
EP2328656A1 (en) 2011-06-08
EA201170484A1 (ru) 2012-03-30
WO2010036799A1 (en) 2010-04-01
US20130101554A1 (en) 2013-04-25
AU2009296653A1 (en) 2010-04-01
KR20110074870A (ko) 2011-07-04
US8871812B2 (en) 2014-10-28
IL211810A0 (en) 2011-06-30
CN102316935A (zh) 2012-01-11
US20110236351A1 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
RU2393863C2 (ru) Лекарственные формы
US8871812B2 (en) Therapeutic regimen comprising PEG-interferon, ribavirin and VX-950 for the treatment of hepatitis
US20100189688A1 (en) Dose forms comprising VX-950 and their dosage regimen
US8664273B2 (en) Treatment of hepatitis C virus with telaprevir (VX-950) in patients non-responsive to treatment with pegylated interferon-alpha 2A/2B and ribavirin
HK1165739A (en) Therapeutic regimen comprising peg- interferon, ribavirin and vx-950 for the treatment of hepatitis
HK1158507A (en) Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interferon-alpha-2a/2b and ribavirin
HK1148962A (en) Dose forms comprising vx-950 and their dosage regimen
AU2012200942A1 (en) Dose forms comprising VX-950 and their dosage regimen
HK1178451A (en) Dose forms comprising vx-950 and their dosage regimen

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120921

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140303

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141118